Identity
- Trade Name
- LIAISON® FT3 FDA UDI
- Generic Name
- Free triiodothyronine (FT3) IVD, kit, chemiluminescent immunoassay FDA UDI
- Model / Reference
- 311531 FDA UDI
Identifiers
- Primary DI / UDI-DI
- 08056771200288 FDA UDI
- GMDN Term
- Free triiodothyronine (FT3) IVD, kit, chemiluminescent immunoassay FDA UDI
Classification
- Commercial Distribution
- In Commercial Distribution FDA UDI
Clinical & Handling
Sterile
No
FDA UDI
Single Use
No
FDA UDI
Implantable
No
FDA UDI
Contains Latex
No
FDA UDI
Prescription Use
No
FDA UDI
Over-the-Counter
No
FDA UDI
Convenience Kit
Yes
FDA UDI
Combination Product
No
FDA UDI
HCT/P
No
FDA UDI
Premarket Exempt
No
FDA UDI
Lot / Batch Number
Yes
FDA UDI
Serial Number
No
FDA UDI
Expiration Date
Yes
FDA UDI
Manufacturing Date
No
FDA UDI
Category: Free triiodothyronine (FT3) IVD, kit, chemiluminescent immunoassay
Liaison® Ft3 by Diasorin Inc. — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS
Similar devices
Also classified as Free triiodothyronine (FT3) IVD, kit, chemiluminescent immunoassay.
- iFlash-FT3 — Shenzhen YHLO Biotech Co., Ltd. · Class II
- ADVIA Centaur® FT3 — Siemens Healthcare Diagnostics · Class II
- Free T3 AccuLite CLIA Test System - 96 Wells — MONOBIND, INC. · Class II
- VITROS — Ortho-Clinical Diagnostics · Class II
- ADVIA Centaur® FT3 — Siemens Healthcare Diagnostics · Class II
- IMMULITE® 2000 Systems FT3 Free T3 — SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS LTD · Class II
- Elecsys FT3 III — Roche Diagnostics Corp. · Class II
- Atellica IM FT3 — Siemens Healthcare Diagnostics · Class II
Authorization Coverage (1 country)
Regulatory Authorizations
United States Pending data
FDA UDI
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA UDI | United States | FDA UDI | Registered in GUDID | N/A | Pending data |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Diasorin Inc.
Sources (1)
- FDA UDI 1e75014c-5db0-4571-b4d6-a7d66636f972 33 fields · synced May 30, 2026